ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Tuesday, November 9, 2021

8:30AM-10:30AM: Abstract Number: 1823

Efficacy of Upadacitinib in Patients with Active Psoriatic Arthritis and a Low or High Swollen Joint Count: A Subgroup Analysis of 2 Phase 3 Studies

Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

8:30AM-10:30AM: Abstract Number: 1752

Efficacy of Voclosporin in Recent Onset Lupus Nephritis

SLE – Treatment Poster (1732–1772)

8:30AM-10:30AM: Abstract Number: 1571

Elevated Lactate, Procalcitonin Levels and SIRS (Systemic Inflammatory Response Syndrome) in a Subset of Patients with Gout

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II (1565–1583)

8:30AM-10:30AM: Abstract Number: 1645

Elevations in Adipocytokines and Mortality in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)

8:30AM-10:30AM: Abstract Number: 1518

Elucidating Activated Osteoarthritis as an Emerging Immune Checkpoint Inhibitor Toxicity: A Descriptive Observational Study

Immunological Complications of Therapy Poster (1516–1529)

8:30AM-10:30AM: Abstract Number: 1543

Epidemiology and Disease Burden of Hospitalized Children with Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 Infection in Canada: A Canadian Pediatric Surveillance Program National Prospective Study

Infection-related Rheumatic Disease Poster (1530–1564)

8:30AM-10:30AM: Abstract Number: 1633

Epidemiology of Musculoskeletal Manifestations in Paediatric Inflammatory Bowel Disease: A Systematic Review

Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

8:30AM-10:30AM: Abstract Number: 1861

Epidermal Growth Factor Receptor Pathway and Fibrosis in Systemic Sclerosis Skin

Systemic Sclerosis & Related Disorders – Clinical Poster III (1836–1861)

8:30AM-10:30AM: Abstract Number: 1512

Epigenetic and Transcriptional Programs of CD4+ T Cell Anergy

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (1507–1515)

8:30AM-10:30AM: Abstract Number: 1695

Erythrocyte Methotrexate Polyglutamates Are Substantially Higher After Subcutaneous Methotrexate Treatment in Rheumatoid Arthritis Patients in the First Months of Treatment

RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)

8:30AM-10:30AM: Abstract Number: 1764

Estimation of the Prevalence of Hydroxychloroquine-Induced Retinopathy in a Cohort of Hydroxychloroquine-Compliant Patients

SLE – Treatment Poster (1732–1772)

8:30AM-10:30AM: Abstract Number: 1701

Evaluation of Cardiovascular Risk Factors and Atherosclerosis in Rheumatoid Arthritis Patients, Treated with Biological Agents: 6-month Follow-up

RA – Treatments Poster III: RA Treatments & Their Safety (1674–1710)

8:30AM-10:30AM: Abstract Number: 1530

Evaluation of the Possible Different Evolution of SARS-CoV-2 Infection with Tumor Necrosis Factor Inhibitors or with Rituximab in Rheumatic Patients

Infection-related Rheumatic Disease Poster (1530–1564)

8:30AM-10:30AM: Abstract Number: 1887

Evidence-Based Behçet’s Disease Activity Scale (EBDA) – A New Instrument with Improved Acuity for Major Organ Disease Activity and Remission Depth Assessment

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

8:30AM-10:30AM: Abstract Number: 1549

Experience from a Diverse Rheumatology Cohort with COVID-19: Are We Doing Better Than We Expected?

Infection-related Rheumatic Disease Poster (1530–1564)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].